Immunovant

IMMUNOVANT INC

Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).

IMVT

Biotech

News

Health Care

General

ROIV

Immunovant&#39;s batoclimab showed positive Phase 3 results in MG but won&#39;t be pursued for approval as the company shifts focus to its lead asset, IMVT-1402.

Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data

Earnings

Earnings Beats

Large Cap

Mid Cap

Small Cap

Markets

Analyst Ratings

Trading Ideas

FULC

ILMN

KRYS

Shares of Immunovant (NASDAQ: IMVT) are rising in the pre-market hours on Sept. 9 after the company announced positive data from the mid-stage study of its investigational candidate, batoclimab, which is being developed for Graves&#39; Disease.

IMVT Stock Up on Upbeat Data From Graves&#39; Disease Study of Batoclimab

Movers

Immunovant reports promising Phase 2a trial results for batoclimab in treating Graves&#39; Disease, showing a high response rate and significant IgG reduction. A pivotal trial is expected to start by the end of 2024.

What&#39;s Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?

Immunovant Inc

Press Releases

Ankyra Announces Appointment of Dr. Julia Butchko and Ms. Tara Withington to the Board of Directors

Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting

Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

Immunovant Announces $450 Million Private Placement

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

Immunovant Reports Financial Results for the Quarter Ended December 31, 2024

Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

Comments

Immunovant

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga